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Process for the preparation of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, methanesulfonate, trihydrate
Field of the invention:
The present invention relates to the process for the preparation of 5-[2-[4-(1,2benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one,
methanesulfonate, trihydrate which is represented by the following structural formula-1a.

Formula-1a

Background of the invention:
Ziprasidone is chemically known as 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl] ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one

compound

of

formula-1.

Ziprasidone

is

indicated for the treatment of schizophrenia.

Formula-1
Ziprasidone compound of formula-1 and pharmaceutically acceptable salts thereof are
disclosed in US Patent 4831031 which describes the preparation of compound of formula-1.
US patent 6399777 describes the anhydrous crystalline form of Ziprasidone mesylate and US
patent 6110918 describes the crystalline form of Ziprasidone mesylate trihydrate. The
structure of compound of formula-1a is
1
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Formula-1a.
US patent 6110918 describes the process for the preparation of crystalline form of
Ziprasidone mesylate trihydrate of formula-1a using Ziprasidone, tetrahydrofuran, methane
sulfonic acid and sterile water for injection.

Brief description of the invention:
The first embodiment of the present invention is to provide a process for the
preparation of Ziprasidone mesylate trihydrate.

Brief description of the Drawings:
Figure 1: Illustrates the PXRD pattern of Ziprasidone mesylate trihydrate.

Detailed description of the invention:
The first embodiment of the present invention provides a process for preparation of
Ziprasidone mesylate trihydrate comprising:
a) suspending Ziprasidone of formula-1 in a mixture of alcohol solvent and water,
b) adding methane sulfonic acid or solution of methane sulfonic acid in water to the mixture
obtained in step a),
c) isolating Ziprasidone mesylate trihydrate of formula-1a from solution of step b).
Alcohol solvent in step a) is selected from methanol, ethanol, isopropanol, n-butanol,
isobutanol, tert-butanol and mixtures thereof; isolating the compound of formula-1a in stepc) is by solvent removal by known techniques which are selected from filtration, or cooling
the mixture to lower temperatures to precipitate the solid followed by filtration of the
2
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mixture or by crystallization. Optionally heating the mixture obtained in step-a) to 60-80°C.

"Pure" or "substantially pure" means Ziprasidone mesylate trihydrate compound of
formula-1a prepared by the process of the present invention is substantially free from the
impurities. The compound of formula-1a obtained according to the present invention is
substantially pure having a purity greater than about 95% by HPLC, preferably greater than
about 97% by HPLC, more preferably greater than about 99% by HPLC.
HPLC [High performance liquid chromatography] method can be carried out by
known techniques.
The impurities, starting materials and by-products formed during the synthesis of
compound of formula-1a are well controlled as per ICH guide lines.
Ziprasidone used as an input for the preparation of Ziprasidone mesylate trihydrate
obtained according to the present invention is prepared by any of the processes disclosed in
literature such as US4831031 or other references or as per process described in the present
specification.
PXRD analysis of the present invention was carried out using BRUKER D8
ADVANCED/AXS X-Ray diffractometer using Cu Kα radiation of wavelength 1.5406 A°
and continuous scan speed of 0.03°/min.
Compound of formula-1a of the present invention is useful and well suitable for the
preparation of various pharmaceutical compositions formulated in a manner suitable for the
route of administration to be used where at least a portion of compound of formula-1a
is present in the composition. Such pharmaceutical compositions may comprise compound of
formula-1a present in the composition in a range of between 0.005% and 100% (wt/wt), with
the balance of the pharmaceutical composition comprising additional substances such as
excipients, diluents, lubricants, binders, wetting agents, disintegrating agents, glidants,
3
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sweetening agents, flavoring agents, emulsifying agents, solubilizing agents, pH buffering
agents, perfuming agents, surface stabilizing agents, suspending agents and other
conventional pharmaceutically inactive agents.
The compound of formula-1a of the present invention can be further micronized or
milled to get desired particle size to achieve desired solubility profile based on different
forms of pharmaceutical composition requirements. Techniques that may be used for particle
size reduction includes but not limited to single or multi-stage micronization using cutting
mills, pin/cage mills, hammer mills, jet mills, fluidized bed jet mills, ball mills and roller
mills. Milling or micronization may be performed before drying or after drying of the
product.
Ziprasidone mesylate trihydrate obtained according to the present invention has
particle size of less than about 250 μm or less than about 200 μm or less than about 150 μm
or less than about 100 μm or less than about 50 μm or any other suitable particle sizes.
The process described in the present invention is demonstrated in examples illustrated
below. These examples are provided as illustration only and therefore should not construed
as limitation of the scope of the invention.

Examples:
Example-1: Preparation of 6-chloro-5-(2-chloroethyl)indolin-2-one
Mixture of 6-chloro-5-(2-chloroacetyl)indolin-2-one (50 g), trifluoro acetic acid (175 ml) and
triethylsilane (57.17 g) at 25-30°C was heated to 45-50°C and stirred for 5 hours at the same
temperature. Cooled the reaction mixture to 25-30°C, methanol was added, cooled to 0-5°C
and stirred for 90 minutes at the same temperature. Filtered the solid, washed with methanol
and followed by with water and dried to get the title compound.
Yield: 46 g; M.R: 215-225°C and HPLC purity: 99.15%.
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Example-2:

Preparation

of

5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-

chloro-1,3-dihydro-2H-indol-2-one or Ziprasidone
Mixture of 3-(piperazin-1-yl)benzo[d]isothiazole (104.84 g),

6-chloro-5-(2-chloroethyl)

indolin-2-one (100 g), water (2000 ml), sodium iodide (6.51 g) and sodium carbonate (138.2
g) was heated to 100-105°C and stirred for 16 hours at the same temperature. Cooled the
reaction mixture 50-55°C and stirred for 1 hour at the same temperature. Filtered the solid
and washed with water. Water was added to the obtained solid at 25-30°C, raised the
temperature to 50-55°C and stirred for 60 minutes at the same temperature. Filter the solid
and washed with water. Isopropanol was added to the obtained solid, raised the temperature
to 50-55°C and stirred for 60 minutes at the same temperature. Cooled the reaction to 2530°C and stirred for 90 minutes at the same temperature. Filtered the solid, washed with
isopropanol and dried to get title compound.
Example-3: Purification of Ziprasidone
Tetrahydrofuran (4300 ml) and water (320 ml) were added to the compound obtained in
Example-2, raised the temperature to 65-70°C and stirred for 15 minutes at the same
temperature. Carbon (8 g) was added to the reaction and filter through the hyflow bed and
washed with tetrahydrofuran. Distilled off solvent from the obtained filtrate and cooled the
obtained residue to 25-30°C. To this obtained residue tetrahydrofuran (750 ml) was added
and stirred for 10 minutes at the same temperature. Cooled the mixture to 0-5°C and stirred
for 2 hours at the same temperature. Filtered the solid, washed with tetrahydrofuran and
dried to get the pure title compound.
Yield: 126 g; M.R: 222-226°C.
Example-4: Preparation of Ziprasidone mesylate trihydrate
A mixture of Ziprasidone (35 g), isopropanol (210 ml) and water (192.5 ml) was stirred at
25-30°C for 10 minutes and heated the mixture to 55-60°C. To this mixture at 55-60°C dilute
methane sulfonic acid solution (9.7 g of methane sulfonic acid in 17.5 ml of water) was
added, heated the mixture to 70-75°C and stirred for 10 minutes at the same temperature.
Filtered the mixture, obtained filtrate was cooled to 25-30°C and stirred for 1 hour at the
5
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same temperature. Filtered the precipitated solid, washed with mixture of isopropanol and
water and dried to get the title compound.
Yield: 36 g; Purity by HPLC: 99.90%; PXRD of the obtained compound is as illustrated in
figure-1.
Example-5: Preparation of 6-chloro-5-(2-chloroethyl)indolin-2-one
Mixture of 6-chloro-5-(2-chloroacetyl)indolin-2-one (35 g), trifluoro acetic acid (122.5 ml)
and triethylsilane (40.2 g) at 25-30°C was heated to 55-60°C and stirred for 6 hours at the
same temperature. Cooled the reaction mixture to 20-25°C and filter the solid. Trifluoro
acetic acid (122.5 ml) and triethyl silane (8.33 g) were added to the obtained solid at 2530°C, heated the reaction mixture to 55-60°C and stirred for 6 hours at the same temperature.
Cooled the reaction mixture to 25-30°C, water added to it and stirred for 90 minutes at the
same temperature. Filter the solid and washed with water. Methanol was added to the
obtained compound at 25-30°C, heated to 65-70°C and stirred. Cooled the mixture to 2530°C and stirred. Filtered the solid, washed with methanol and followed by with water and
dried to get the title compound.
Yield: 25 g; M.R: 215-225°C and HPLC purity: 99.72%.

Example-6:

Preparation

of

5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-

chloro-1,3-dihydro-2H-indol-2-one or Ziprasidone
Mixture of 3-(piperazin-1-yl)benzo[d]isothiazole (115.3 g),

6-chloro-5-(2-chloroethyl)

indolin-2-one (110 g), water (2200 ml), sodium iodide (7.16 g) and sodium carbonate (152 g)
was heated to 95-100°C and stirred for 14 hours at the same temperature. Cooled the reaction
mixture 60-65°C and stirred for 1 hour at the same temperature. Filtered the solid and
washed with water. Water was added to the obtained solid at 25-30°C, raised the temperature
to 60-65°C and stirred for 60 minutes at the same temperature. Filter the solid and washed
with water. Isopropanol was added to the obtained solid, raised the temperature to 80-85°C
and stirred for 60 minutes at the same temperature. Cooled the reaction to 40-45°C and
stirred for 90 minutes at the same temperature. Filtered the solid, washed with isopropanol
6
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and dried to get title compound.
Yield: 140 g
Example-7: Purification of Ziprasidone
Tetrahydrofuran (4730 ml) and water (352 ml) were added to the compound obtained in
Example-5, raised the temperature to 65-70°C and stirred for 15 minutes at the same
temperature. Carbon (8.8 g) was added to the reaction and filter through the hyflow bed and
washed with tetrahydrofuran. Partially distilled off solvent from the obtained filtrate and
cooled to 25-30°C. To this obtained mixture was cooled to 0-5°C and stirred for 2 hours at
the same temperature. Filtered the solid, washed with tetrahydrofuran and dried to get the
pure title compound.
Yield: 125 g; M.R: 220-226°C; purity by HPLC: 99.61%
Example-8: Preparation of Ziprasidone mesylate trihydrate
A mixture of Ziprasidone (50 g), isopropanol (300 ml) and water (300 ml) was stirred at 2530°C for 10 minutes and heated the mixture to 75-80°C. To this mixture at 75-80°C methane
sulfonic acid (12.80 g) was added and stirred for 10 minutes at the same temperature. Carbon
treatment was given to reaction mixture. Cooled the mixture to 25-30°C and stirred for 90
minutes at the same temperature. Filtered the precipitated solid, washed with mixture of
isopropanol and water and dried to get the title compound.
Yield: 57 g; Purity by HPLC: 99.94%; Particle size distribution: Dv(10):4.84 μm, Dv(50):
24.7 μm, Dv(90): 70.8 μm; PXRD of the obtained compound is as illustrated in figure-1.
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Drawings

Figure-1

*****

8

https://www.tdcommons.org/dpubs_series/3953

9

